Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as taranabant
MK0364 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| taranabant | DRUG | - |
| MK0364 | DRUG | - |
Inclusion Criteria: * Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea). Exclusion Criteria: * Patients with serious or unsta...
Top 20 of 35 competitors
MK0364 is an investigational small molecule being developed for the treatment of obesity. It is intended for patients who are considerably overweight. The drug is currently in Phase 2 clinical development and has not been approved by the FDA.
MK0364 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in obese patients.
MK0364 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The drug is being studied for its potential use in treating obesity, and its development is ongoing.
MK0364 has been studied in one completed Phase 2 clinical trial with the identifier NCT00109148. This trial, titled "An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)," enrolled 500 participants aged 18 years and older with obesity.
Yes, the clinical trial for MK0364 was randomized and double-blind, meaning participants were randomly assigned to treatment groups and neither the participants nor the researchers knew which treatment was given. The trial was uncontrolled, meaning there was no placebo or active comparator group.